Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer-Reference-Cited by-同舟云学术

Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer

Published:2023-08-25 Issue:16 Volume:149 Page:15095-15102
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Doubre Hélène,Greillier Laurent,Justeau Grégoire,Ricordel Charles,Swalduz Aurélie,Curcio Hubert,Bylicki Olivier,Auliac Jean-Bernard,Guisier Florian,Bigay-Game Laurence,Bernardi Marie,Pinsolle Julian,Amrane Karim,Decroisette Chantal,Descourt Renaud,Chouaid Christos,Geier Margaux

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-05321-w.pdf

Reference29 articles.

1. Amrane K, Geier M, Corre R, Léna H, Léveiller G, Gadby F et al (2020) First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study. Cancer Med. 9:2309–2316. https://doi.org/10.1002/cam4.2806

2. Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643

3. Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373:123–135. https://doi.org/10.1056/NEJMoa1504627

4. Choi JU, Lee NK, Seo H et al (2021) Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002332

5. Deschenes-Simard X, Richard C, Galland L et al (2021) Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. Thromb Res 205:29–39. https://doi.org/10.1016/j.thromres.2021.06.018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies;Hämostaseologie;2024-01-08